Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Journal Title: Медичні перспективи - Year 2015, Vol 20, Issue 3

Abstract

Aim of this study was to analyze molecular genetic and cytogenetic reasons for disease resistance to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) in patients with chronic myeloid leukemia (CML). Material and methods. A group of 32 CML patients with primary or acquired resistance to TKI treatment was investigated. Cytogenetic response was determined by conventional karyotyping with differential banding. Presence of BCR-ABL kinase domain mutations was investigated by direct sequencing. Results and discussion. The frequency of mutations was 37% (12 patients) with prevailing occurrence of mutations with low sensitivity to nilotinib – E255K/V; Т315I; F359V; Y253H. In 47% of the cases (15 patients) additional chromosome aberrations (ACA) were revealed which could also be the reason for TKI resistance in patients without BCR/ABL mutations. Patients with detected mutations of BCR/ABL gene were either switched to nilotinib or treated with increased dose of IM. Cytogenetic response was achieved in only 2 patients with mutations and in 12 patients without them. Frequency of blast crisis development did not differ significantly in both groups. Conclusions. Among the investigated patients with CML resistant to IM BCR/ABL gene mutations were detected in more than third of the cases whereas ACA were found in almost half of the group. Taking into account revealed prevalence of mutations not sensitive to the 2nd generation TKI nilotinib, investigation of mutational status has to be obligatory in all patients for whom treatment correction is considered. Presence of ACA should also be taken into account in patients requiring administration of the second line TKI since they can adversely influence expected treatment response as well.

Authors and Affiliations

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka , I. Selina, H. Usenko

Keywords

Related Articles

Дніпропетровська гігієнічна школа: минуле, сьогодення, майбутне (до 90-річчя від заснування) 

В статье представлен исторический анализ формирования гигиенической школы Днепропетровской медицинской академии за 100-летний период существования - от образования в XIX веке санитарного земства Катеринославской губернии...

Optimization of diagnostic and treatment algorhythm of blunt thoracic traumas in patients with combined thoracic and brain trauma

Results of treatment of 71 victims with combined blunt thoracic and brain trauma were analysed. In the main group (n=35) there was used algorithm, envisaging videothoracoscopic interventions and widening indications for...

Гігієнічна оцінка безпечності виробничих умов праці в технологічному циклі застосування комбінованого фунгіциду-протруйника на основі тебуконазолу і металаксилу-М на зернових колосових культурах

В статье поднимается вопрос актуальности гигиенического подхода к оценке безопасности для профессиональных контингентов применения комби­нированных фунгицидов на зерновых колосовых культурах. Проведены гигиенические иссл...

Features of cerebral blood flow, cardiac arrhythmias and conduction disturbances in patients with essential hypertension stage II associated with occlusive and stenotic lesions of brachiocephalic arteries

Arterial hypertension is the most common disease of the cardiovascular system in industrially advanced countries. With the aim to determine the characteristics of cerebral blood flow, disorders of cardiac rhythm and cond...

Download PDF file
  • EP ID EP90057
  • DOI -
  • Views 101
  • Downloads 0

How To Cite

K. Kotlyarchuk, Z. Maslyak, A. Lukianova, O. Tsyapka, I. Selina, H. Usenko (2015). Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Медичні перспективи, 20(3), 67-73. https://europub.co.uk/articles/-A-90057